Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical cord-derived MNC versus MSC intrathecal injection for children with spastic cerebral palsy
IRCT201706176907N13Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human umbilical cord mesenchymal stem cells in cerebral palsy (CP) (3 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Motor development alteration, Motor function change and 2 more. Started Nov 2017; status: completed.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
cerebral palsy (CP)
Beyond the preview
Go deeper on IRCT201706176907N13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201706176907N13.